We are thrilled to present to our community the launch of the product VETRANO® palbociclib, for our Oncology Line.

VETRANO® palbociclib is indicated for the treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 (HER2-) negative, metastatic or locally advanced breast cancer.

VETRANO® palbociclib is available in the following dosages:

  • 75 mg x 21 coated tablets
  • 100 mg x 21 coated tablets
  • 125 mg x 21 coated tablets

VETRANO® palbociclib joins the portfolio of products for the treatment of breast cancer, together with DIMERE® fulvestrant, IDELARA® letrozole y ANASTRADEX® anastrozol.

We invite you all to read the following material to learn more about the product!

Bioprofarma Bagó Working in the present, thinking the future.

Bioprofarma Bagó
Trabajando el presente, pensando el futuro.

Noticias relacionadas